Is the current medication regimen of wellbutrin (bupropion) sustained‑release 150 mg twice daily, quetiapine 50 mg at bedtime, and gabapentin 100 mg three times daily appropriate for a patient with major depressive disorder, social phobia, panic attacks, and obsessive‑compulsive disorder?

This Regimen Is Suboptimal and Requires Modification

This medication combination is inadequate for treating major depressive disorder, social phobia, panic attacks, and OCD, as it lacks first-line evidence-based agents for these anxiety disorders and uses medications at doses unlikely to provide therapeutic benefit.

Critical Problems with Current Regimen

Missing First-Line Treatment for Anxiety Disorders

The most significant issue is the absence of an SSRI or SNRI, which are the evidence-based first-line treatments for social phobia, panic disorder, and OCD 1, 2. Bupropion alone is FDA-approved only for major depressive disorder—not for any anxiety disorder 3.

• For OCD specifically: SSRIs are first-line agents, with 8-12 weeks needed to determine efficacy 2. Bupropion has no established role in OCD treatment.
• For social phobia and panic disorder: SSRIs/SNRIs are standard treatment 1, 4. Bupropion's noradrenergic and dopaminergic activity may actually worsen anxiety symptoms in some patients 5, 6.
• The evidence on bupropion and anxiety is mixed: While some studies show it can reduce anxiety in depressed patients with mild-to-moderate anxiety, SSRIs are preferable for severe depression with anxious features 5, 6. In patients with high baseline anxiety, SSRIs show modest advantages over bupropion 5.

Inadequate Dosing of Adjunctive Agents

Quetiapine 50 mg at bedtime is a subtherapeutic dose for any psychiatric indication:

• This dose provides only sedation, not antidepressant or anxiolytic effects 7, 8
• Therapeutic doses for depression/anxiety augmentation typically range from 150-300 mg daily 8
• At 50 mg, you're getting side effects (sedation, metabolic risk) without therapeutic benefit

Gabapentin 100 mg TID (300 mg total daily) is at the lower end of the therapeutic range:

• Evidence for gabapentin in social anxiety disorder uses doses of 900-3600 mg daily 9
• For anxiety symptoms, 900 mg is typically the minimum effective dose 10, 9
• Current dosing (300 mg/day) is unlikely to provide meaningful anxiolytic effect

Recommended Treatment Algorithm

Step 1: Add an SSRI or SNRI as Primary Treatment

Start an SSRI immediately as the foundation for treating all four conditions 1, 2:

• Sertraline 50 mg daily (increase to 100-200 mg) OR
• Escitalopram 10 mg daily (increase to 10-20 mg) OR
• Paroxetine 20 mg daily (increase to 40-60 mg for OCD)

These agents have demonstrated efficacy across MDD, social phobia, panic disorder, and OCD 1, 2. For OCD specifically, higher SSRI doses are often required (e.g., fluoxetine 60-80 mg, paroxetine 40-60 mg) 2.

Step 2: Reassess Bupropion's Role

Continue bupropion SR 150 mg BID initially, as it addresses the MDD component and has lower sexual side effect risk than SSRIs 1. However, monitor closely for:

• Worsening anxiety or agitation (particularly panic symptoms)
• If anxiety worsens significantly, consider reducing or discontinuing bupropion 5, 6

The combination of SSRI + bupropion can be effective for depression and may help mitigate SSRI-induced sexual dysfunction 1.

Step 3: Optimize or Discontinue Current Adjunctive Agents

For quetiapine: Either increase to therapeutic dose (150-300 mg) for augmentation OR discontinue entirely 7, 8:

• If continuing: Target 150-300 mg for antidepressant/anxiolytic effect
• If discontinuing: Taper over 1-2 weeks to avoid withdrawal
• Caution: Monitor for metabolic side effects (weight gain, glucose dysregulation) at higher doses 8

For gabapentin: Either increase to therapeutic dose (900-3600 mg daily) OR discontinue 10, 9:

• If targeting anxiety: Increase to at least 900 mg daily (300 mg TID)
• For sleep disturbance: 300-900 mg at bedtime may suffice 10
• Current dose (100 mg TID) provides minimal benefit

Step 4: Timeline and Monitoring

Week 1-2: Start SSRI, continue current regimen, monitor closely for:

• Suicidal ideation (highest risk in first 1-2 months) 1
• Worsening anxiety or agitation
• Activation syndrome

Week 4-6: Assess initial response 1:

• If inadequate response: Increase SSRI dose
• If anxiety worsening with bupropion: Consider reducing or stopping

Week 8-12: Evaluate full response 1, 2:

• For OCD, full response may take 12 weeks 2
• If partial response: Consider SSRI dose optimization or augmentation strategies
• If no response: Switch to different SSRI or add augmentation

Step 5: If Inadequate Response After 8-12 Weeks

For persistent OCD symptoms after adequate SSRI trial 2:

• Increase SSRI to maximum tolerated dose
• Consider switching to different SSRI or clomipramine
• Augmentation options: Low-dose antipsychotic (risperidone 0.5-3 mg, aripiprazole 5-15 mg)

For persistent depression/anxiety 1:

• Switch to different SSRI/SNRI
• Consider augmentation with atypical antipsychotic at therapeutic doses
• Combine with cognitive-behavioral therapy (CBT is highly effective for all these conditions)

Common Pitfalls to Avoid

1. Using bupropion as monotherapy for anxiety disorders: It lacks evidence and may worsen anxiety 5, 6
2. Subtherapeutic dosing of adjunctive agents: 50 mg quetiapine and 300 mg gabapentin provide minimal benefit while exposing patients to side effects
3. Inadequate SSRI trial duration: Allow 8-12 weeks at therapeutic doses before declaring treatment failure 1, 2
4. Neglecting CBT: Combination of medication + CBT is superior to either alone for anxiety disorders 2
5. Premature polypharmacy: Optimize first-line SSRI before adding multiple adjunctive agents

Maintenance Treatment

Once remission achieved 1:

• First episode MDD: Continue treatment 4-9 months
• Recurrent MDD (≥2 episodes): Consider longer-term maintenance
• OCD: Minimum 12-24 months after remission, often requires longer treatment 2
• Anxiety disorders: Typically 12+ months after symptom resolution

The bottom line: This patient needs an SSRI as the cornerstone of treatment, with bupropion potentially maintained for depression but monitored for anxiety worsening. Current adjunctive agents are either at subtherapeutic doses or should be discontinued.